Probable Antiphospholipid Syndrome Causing Biventricular Thrombi and Cardiogenic Shock Authors: Parth Contractor, Joseph Deng, Liam Parker O’Neill, Esteban Davila, Manu Mysore Published: 2026 ABSTRACT BackgroundIntracardiac thrombi are a rare manifestation of antiphospholipid syndrome (APS), with biventricular involvement being exceedingly uncommon.Case SummaryA 70-year-old woman with recent Takotsubo cardiomyopathy was admitted with cardiogenic shock. Imaging demonstrated large biventricular thrombi. Initial laboratory testing was consistent with probable APS. Inotropic support and anticoagulation were initiated. After failed attempts to wean inotropes, the patient elected hospice care.DiscussionThis case highlights the diagnostic uncertainty and limited evidence guiding management of extensive intracardiac thrombosis in patients with suspected APS presenting with cardiogenic shock. Beyond anticoagulation, the evidence base for managing intracardiac thrombi in probable APS is limited to case reports, and there are large risks associated with invasive strategies for removing intracardiac thrombi.Take-Home MessagesRapid development of extensive multichamber intracardiac and systemic thrombosis should prompt evaluation for APS. Anticoagulation remains the cornerstone of therapy; evidence guiding invasive strategies is limited. History of Presentation A 70-year-old woman presented with 1 week of shortness of breath, dyspnea on exertion, and bilateral lower extremity swelling and was admitted to the intensive care unit for presumed cardiogenic shock. Echocardiography demonstrated a newly reduced ejection fraction of 15% to 20% and large thrombi filling two-thirds of both ventricles. Chest computed tomography angiography revealed bilateral lobar pulmonary artery emboli with right ventricular strain. Past Medical History Notably, 1 month before this admission, the patient had been admitted for chest pain with anterolateral ST-segment depressions on electrocardiogram and a high-sensitivity troponin T level of 966 ng/dL. Left heart catheterization during that admission showed no coronary artery disease, and ventriculogram showed an ejection fraction of 55% with apical hypokinesis concerning for resolving Takotsubo stress-induced cardiomyopathy. During that admission, she was found to have an incidental elevation of absolute eosinophil count to 2.4 × 103/μL (reference range: 0.0-0.2 × 103/μL). Other medical issues included hyperlipidemia, thyroid cancer with subsequent thyroidectomy, breast cancer with subsequent mastectomy, hypothyroidism, gastroesophageal reflux disease, and a family history of antiphospholipid syndrome (APS). Differential Diagnosis The differential diagnosis of the cardiogenic shock with biventricular thrombi included Takotsubo stress-induced cardiomyopathy, myocarditis, eosinophilic cardiomyopathy, APS, and occult malignancy. Investigations Initial laboratory results were notable for an N-terminal pro–B-type natriuretic peptide level of 14,000 pg/mL and moderately elevated anti-cardiolipin IgM at 39 MPL (reference range: <12 MPL), anti-β2-glycoprotein I IgG antibody at 31 SGU (reference range: <20 SGU), and a positive lupus anticoagulant. Repeat antibody testing was not conducted, as the patient passed within 12 weeks of initial testing. Of note, her absolute eosinophil count had normalized at the time of admission and remained normal throughout this hospital stay. Chest computed tomography angiography demonstrated bilateral pulmonary emboli. Ultrasound of the lower extremities revealed extensive deep venous thrombi in bilateral deep femoral veins, right iliac vein, and right peroneal vein. Cardiac magnetic resonance imaging demonstrated no evidence of late gadolinium enhancement but showed thrombi within both ventricles as well as the right atrium, left subclavian vein, left internal jugular vein, and left brachiocephalic vein (Supplemental Figures). Positron emission tomography/computed tomography demonstrated no metabolic evidence of malignancy. Right heart catheterization with biopsy of the ventricular thrombi was considered to rule out eosinophilic cardiomyopathy or other infiltrative process but was deemed too high risk in the setting of severe thrombocytopenia, with a platelet count of 14,000. Because of elevated risk, no invasive hemodynamics were obtained. Management The patient was started on a continuous heparin infusion on admission for the extensive thrombi. Percutaneous thrombectomy of the pulmonary embolism was considered, but the clot size was determined to be too small. Given extensive lower extremity thrombi, an inferior vena cava filter was placed on hospital day 2 to prevent further thrombus formation in the pulmonary vasculature. The patient developed profound thrombocytopenia, with a platelet nadir of 14,000 on hospital day 7. The thrombocytopenia was felt to be multifactorial, related to consumptive coagulopathy from extensive thrombus burden and suspected mechanical platelet destruction, with negative antibody testing for heparin-induced thrombocytopenia. The patient continued to decompensate with worsening shock requiring high-flow nasal cannula and inotropic support with milrinone on hospital day 3. In this patient, shock resulted from several converging physiologic mechanisms. Pulmonary emboli acutely increased right ventricular afterload causing right ventricular dilation, impaired left ventricular filling, and ultimately biventricular dysfunction. Intracardiac thrombi further compromised hemodynamics through direct flow obstruction. Hematology-oncology was consulted for the diffuse hypercoagulability and believed the patient's presentation was consistent with probable APS causing widespread thrombi and acute cardiogenic shock. Plasma exchange was discussed as a potential treatment with large clot burden, but the patient declined stating it was not within goals of care. Thrombectomy was also felt to be not aligned with goals of care. Outcome and Follow-Up Despite inotropic support, the patient experienced progressive worsening of fatigue, shortness of breath, and lower extremity edema. It was determined that she would likely be inotrope-dependent long term after several attempts to wean on hospital days 5 to 10 failed. Palliative care was engaged, and after extensive discussion, the patient elected to pursue comfort measures and inpatient hospice. Given the decision to transition to hospice care, no long-term anticoagulation strategy was discussed. The patient ultimately passed away on hospital day 20. While cardiac biopsy could have provided a more definitive diagnosis, the presumed cause of the extensive hypercoagulability and cardiogenic shock was thought to be probable APS given the moderately positive anti-cardiolipin IgM, anti-β2-glycoprotein I IgG, and lupus anticoagulant. Discussion Intracardiac thrombi are a recognized but uncommon manifestation of probable antiphospholipid syndrome, and simultaneous multichamber involvement is exceedingly rare.1 Previously documented cases are primarily in young and middle-aged female patients. Reported cases describe heterogeneous presentations including dyspnea, fever, hemiparesis, limb ischemia, and cardiogenic shock,2 In probable APS, antiphospholipid antibodies promote thrombosis through complement activation, endothelial dysfunction, and platelet activation, creating a systemic hypercoagulable state. When combined with intracardiac stasis from impaired ventricular function, this prothrombotic milieu predisposes to thrombus formation. Most reported APS-related intracardiac thrombi involve the left ventricle and occur in the setting of reduced ejection fraction or valvular abnormalities.3 Our patient's case is notable both for the extent of thrombus—left and right ventricles, right atrium, and across an inferior vena cava filter—and the rapid development of clot burden within weeks of a previously normal echocardiogram during her admission for Takotsubo stress-induced cardiomyopathy. Biventricular thrombi in APS are exceedingly rare, with no specific cases documented in the literature. Although ventricular dysfunction is a recognized manifestation of APS through microthrombotic mechanisms, the concurrent presentation of biventricular thrombi has not previously been reported. Given the unusual presentation, establishing probable APS as the unifying etiology of her multichamber thrombi required careful exclusion of alternative causes. The differential diagnosis for biventricular thrombi includes ischemic and nonischemic cardiomyopathies, myocarditis, hypereosinophilic syndromes, malignancy-associated thrombosis, right-heart strain from pulmonary embolism, and Takotsubo stress-induced cardiomyopathy. Cardiac magnetic resonance imaging did not support infiltrative disease or eosinophilic myocarditis; eosinophilia was mild and transient, and malignancy evaluation was unremarkable. Recurrent Takotsubo stress-induced cardiomyopathy was considered, but her rapid normalization of ejection fraction after the August hospitalization made this less likely. APS itself has been described as a rare cause of cardiomyopathy, attributed to recurrent microvascular ischemia or myocarditis-like myocardial injury.4 Taken together with her serologic profile and family history, probable APS most convincingly explained both her ventricular dysfunction and extensive multichamber thrombosis. Catastrophic APS was considered; however, the patient lacked evidence of rapidly progressive multiorgan failure, biopsy-proven small-vessel thrombosis, or microangiopathic hemolytic anemia.5,6 Once probable APS was identified as the underlying diagnosis, therapeutic decision-making centered on evidence-based management of APS-associated intracardiac thrombi. First-line treatment for left ventricular thrombus in general is full-dose anticoagulation, typically with a vitamin K antagonist (VKA) targeting an international normalized ratio (INR) of 2-3, or a full-dose direct oral anticoagulant.7 In patients with APS, the treatment is narrowed to VKAs given increased odds of arterial thrombosis in those taking direct oral anticoagulants.8 The standard approach is to target a goal INR of 2-3 for venous events and consider a higher target (3-4) for recurrent thrombosis. In the acute setting, unfractionated heparin or low-molecular-weight heparin is preferred. Beyond anticoagulation, the evidence base for managing intracardiac thrombi in APS is sparse. Thrombolytics lack supporting data in this context, and reports of their use are limited. Surgical thrombectomy may be considered in cases of hemodynamic compromise, highly mobile thrombi, or failure of medical therapy, but published experience in APS is limited. Vacuum-assisted aspiration systems have demonstrated success primarily in right-sided thrombi in non-APS populations, but their role in APS remains undefined, with few published cases to guide management.9,10 Use of mechanical circulatory support in APS with cardiac involvement is extremely rare. APS adds unique hazards to these procedures: Extracorporeal circuits and large-bore access may potentiate thrombosis, and device surfaces can trigger procoagulant cascades. Moreover, extensive multichamber clot burden poses formidable technical and embolic risk. In this patient, the extensive multichamber clot burden and hemodynamic vulnerability made mechanical intervention technically challenging and potentially high risk. In the absence of obstruction, embolization, or failure of anticoagulation, systemic VKA-based therapy remains the most evidence-supported and clinically prudent first-line strategy. This case underscores the importance of recognizing APS as a potential cause of rapidly progressive intracardiac thrombosis and prioritizing anticoagulation as the cornerstone of management. Conclusions We describe to our knowledge the first published case of biventricular thrombi in probable APS. Clinicians should maintain a high index of suspicion for APS-spectrum disease in patients with rapidly progressive intracardiac thrombosis. This case emphasizes early anticoagulation, cautious avoidance of invasive strategies in high-risk anatomy, and recognition of the limitations of current evidence when managing suspected APS in critically ill patients. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.Take-Home Messages•Rapid development of extensive multichamber intracardiac and systemic thrombosis should prompt evaluation for antiphospholipid syndrome.•Anticoagulation remains the cornerstone of therapy; evidence guiding invasive strategies is limited. Take-Home Messages •Rapid development of extensive multichamber intracardiac and systemic thrombosis should prompt evaluation for antiphospholipid syndrome.•Anticoagulation remains the cornerstone of therapy; evidence guiding invasive strategies is limited. •Rapid development of extensive multichamber intracardiac and systemic thrombosis should prompt evaluation for antiphospholipid syndrome. Rapid development of extensive multichamber intracardiac and systemic thrombosis should prompt evaluation for antiphospholipid syndrome. •Anticoagulation remains the cornerstone of therapy; evidence guiding invasive strategies is limited. Anticoagulation remains the cornerstone of therapy; evidence guiding invasive strategies is limited.